The FDA has accepted GSK’s application for priority review for extended use of Arexvy in higher-risk adults aged 50 to 59 years; pharmacy retail chains are finding it harder to draw the next generation of pharmacists; antivaccine activists are falsely downplaying the dangers of measles amid global outbreaks.
The chain drug stores are having issues with hiring and retaining pharmacists these days, and it eventually could become a problem for many of you when needing to fill a prescription.